Mineralys Therapeutics is a publicly traded, clinical-stage biotechnology company dedicated to developing innovative medicines that target diseases associated with abnormally elevated aldosterone levels. The company's lead product candidate, lorundrostat, is a proprietary, orally administered aldosterone synthase inhibitor aimed at treating cardiorenal conditions such as hypertension and chronic kidney disease. Operating as a fully remote organization, Mineralys Therapeutics emphasizes a dynamic and entrepreneurial work environment, fostering creativity and collaboration in its mission to improve patient outcomes.